소아기에 발생한 성장호르몬 결핍증 성인 환자에서성장호르몬 치료가 골밀도에 미치는 영향
The Effect of Growth Hormone Therapy on Bone Mineral Density inYoung Adults with Childhood-onset Growth Hormone Deficiency
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose : Growth hormone (GH) has multiple beneficial effects in addition to its promotion of linear growth. Therefore adults with GH deficiency (GHD) have abnormal body composition, altered lipid metabolism, increased cardiovascular disease, and decreased bone mineral density (BMD). We evaluated the effect of GH therapy on BMD in young adults with childhood-onset GHD. Methods : 17 childhood-onset GHD adults (10 male, 7 female, mean age 24.5±5.5 yr) with or without continuous GH treatment after final height were studied. All subjects divided two groups; GH-treated group (n=6) and GH-untreated group (n=11). BMD in lumbar spine and proximal femur was measured by dual energy X-ray absorptiometry. Results : The mean serum level of IGF-I concentration in the GH-untreated group was lower than in the GH-treated group (88.4±55.9 ng/mL vs. 358.7±196.8 ng/mL, P<0.05). The BMD of lumbar spine in the GH-treated group and GH-untreated group was 1.02±0.13 g/cm2 and 0.82±0.09 g/cm2 and the BMD of femur was 1.15±0.14 g/cm2 and 0.82±0.10 g/cm2 respectively. The BMD of the GH-treated group was significantly higher than the GH-untreated group (P<0.05). Conclusion : These findings support the need of continuous GH treatment after completion of growth and careful evaluation of BMD in adult patients with childhood-onset GHD.
Abstract
Purpose : Growth hormone (GH) has multiple beneficial effects in addition to its promotion of linear growth. Therefore adults with GH deficiency (GHD) have abnormal body composition, altered lipid metabolism, increased cardiovascular disease, and decreased bone mineral density (BMD). We evaluated the effect of GH therapy on BMD in young adults with childhood-onset GHD. Methods : 17 childhood-onset GHD adults (10 male, 7 female, mean age 24.5±5.5 yr) with or without continuous GH treatment after final height were studied. All subjects divided two groups; GH-treated group (n=6) and GH-untreated group (n=11). BMD in lumbar spine and proximal femur was measured by dual energy X-ray absorptiometry. Results : The mean serum level of IGF-I concentration in the GH-untreated group was lower than in the GH-treated group (88.4±55.9 ng/mL vs. 358.7±196.8 ng/mL, P<0.05). The BMD of lumbar spine in the GH-treated group and GH-untreated group was 1.02±0.13 g/cm2 and 0.82±0.09 g/cm2 and the BMD of femur was 1.15±0.14 g/cm2 and 0.82±0.10 g/cm2 respectively. The BMD of the GH-treated group was significantly higher than the GH-untreated group (P<0.05). Conclusion : These findings support the need of continuous GH treatment after completion of growth and careful evaluation of BMD in adult patients with childhood-onset GHD.
참고문헌 (23)
- Tauber M., "Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment", J Clin Endoclinol Metab, 82, pp.352~356 (1997)
- Longobardi S., "Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood", J Clin Endocrinol Metab, 81, pp.1244~1247 (1996)
- Nicolson A., "The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood", Clin Endocrinol (oxf), 44, pp.311~316 (1996)
- Aimaretti G., "Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH releasing-hormone-plus arginine test", J Clin Endoclinol Metab, 85, pp.3693~3699 (2000)
- Cuneo R.C., "The growth hormone deficiency syndrome in adults", Clin Endocrinol (Oxf), 37, pp.387~397 (1992)
- de Boer H., "Clinical aspects of growth hormone deficiency in adults", Endocr Rev, 16, pp.63~-86 (1995)
- Clayton P.E., "Consensus statement on the management of the GH-treated adolescent in the transition to adult care", Eur J Endocrinol, 152, pp.165~170 (2005)
- Carroll P.V., "Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee", J Clinical Endoclinol Metab, 83, pp.382~395 (1998)
- Drake W.M., "The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficiency adolescents at the completion of linear growth", J Clin Endocrionol Metab, 88, pp.1658~1663 (2003)
- Bonjour J.P., "Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence", J Clin Endoclinol Metab, 73, pp.555~563 (1991)
- Matkovic V., "Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis, Inference from a cross-sectional model", J Clin Invest, 93, pp.799~808 (1994)
- Kim D.H., "Reassessment of growth hormone (GH) status and metabolic disturbance in young adults with childhood-onset GH deficiency", J Korean Soc Pediatr Endocrinol, 7, pp.190~198 (2002)
- Jung M.H., "Cardiovascular abnormalities after discontinuation of growth hormone treatment in adults with childhood-onset growth hormone deficiency", J Korean Soc Peiatr Endocrinol, 8, pp.46~55 (2003)
- World Health Organization, "WHO Technical Repor Series 843. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis", Geneva Switzerland: World health Organ Tech Rep Ser, 843, pp.1~129 (1994)
- Theintz G., "Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects", J Clin Endocrinol Metab, 75, pp.1060~1065 (1992)
- Ohlsson C., "Andreassen TT, Slootweg MC. Growth hormone and bone", Endocr Rev, 19, pp.55~79 (1998)
- Boot A.M., "Changes in bone mineral density, body composition, and lipid metabolism durine growth hormone (GH) treatment in children with GH deficiency", J Clinic Endocrin Metab, 82, pp.2423~2428 (1997)
- Baroncelli G.I., "Dynamics of bone turnover in children with GH deficiency treated with GH until final height", Eur J Endocrinol, 142, pp.549~556 (2000)
- Kassem M., "Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro", Growth Regul, 4, pp.131~135 (1994)
- Brixen K., "A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers", J Bone Miner Res, 5, pp.609~618 (1990)
- Hausen T.B., "Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study", J Clin Endocrinol Metab, 81, pp.3352~3359 (1996)
- Underwood L.E., "Genentech Collaborative Study Group. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study", J Clin Endocrinol Metab, 88, pp.5273~5280 (2003)
- Shalet S.M., "Effect of growth hormone (GH) treatment on bone in postpubertal GH- deficency patients: a 2-year randomized, controlled, dose-ranging study", J Clin Endocrinol Metab, 88, pp.4124~4129 (2003)